Jumpstart Fertility
Turning back the clock on egg quality, to make IVF work for women over 37
At a glance
-
Development stage
Prototype developed
-
Investment stage
Series B
-
Commercialisation pathway
Spinout - staff led
-
Technology readiness level
TRL 6
-
Female led
Yes
Jumpstart Fertility is developing a new approach to address age-related metabolic decline in oocytes and improve IVF outcomes for women over 37.
-
Jumpstart Fertility has developed a patented NAD+ precursor that restores age-related metabolic decline in human oocytes (eggs) — a core biological driver of fertility decline. Pre-formulated into a single-step embryo culture media additive, it integrates into existing IVF workflows with no change to protocol.
Pre-clinical models show a 20–30% absolute increase in blastocyst formation, cutting IVF cycles per live birth in women 37+ by around 55%. Revenue comes from per-cycle media sales and manufacturer licensing/ royalty agreements.
-
The IVF treatment market lacks an effective solution for its fastest-growing patient segment: women aged 37+, who now make up to 40% of IVF patients in major markets. Declining egg quality drives repeated, costly cycles — US patients average 5.5 cycles per live birth, costing over US$84,500.
-
Global embryo culture media manufacturers and fertility clinics serving women aged 37+, who represent up to 40% of IVF patients in major markets.
-
- Five granted composition-of-matter patent families globally
- Japan clinical study ethics-approved; patient enrolment targeted Q3 2026
- Partnership pathway underway with a global IVF media manufacturer
Discover more UNSW spinouts
Search our catalogue of active spinouts and tech for license.